Withings Introduces Abbott’s Lingo Biosensor for Non-Invasive Glucose Management, Targeting 70-140 mg/dL Range

July 26, 2026

Withings France

Overview

Withings introduces Abbott’s Lingo as a non-invasive continuous glucose monitor (CGM) biosensor. Lingo painlessly attaches to the upper arm, streaming real-time glucose data to the Lingo app. This allows users to understand how diet, exercise, and stress impact their metabolic health, gaining insights to maintain glucose levels within a healthy range (70-140 mg/dL). Lingo provides an accessible health management solution for individuals aiming to improve fuel management, focus, and heart health.

In Depth

Key Findings

Withings is featuring Abbott’s Lingo, a non-invasive continuous glucose monitor (CGM) biosensor, designed to provide users with real-time glucose data without pain, thereby enabling a comprehensive understanding of metabolic health. Worn on the upper arm, Lingo aims to help users maintain glucose levels within a healthy range of 70-140 mg/dL, contributing to improved fuel management, focus, and cardiovascular health.

Technical and Clinical Details

The Lingo biosensor employs proprietary non-invasive technology to measure glucose levels at the skin surface, wirelessly streaming this data to the dedicated Lingo app. Unlike traditional CGMs that require subcutaneous insertion, Lingo eliminates the need for needles, significantly reducing discomfort upon wear. Beyond real-time glucose display, the app analyzes correlations between lifestyle factors such as diet, exercise, sleep, and stress with blood glucose fluctuations, providing personalized insights. For instance, users can visually understand glucose spikes after specific carbohydrate intake or the stabilizing effects of exercise. This empowers users to implement concrete behavioral changes and gain the knowledge and tools necessary for optimal metabolic self-management.

Background and Industry Context

Continuous glucose monitoring is increasingly recognized as a powerful tool not only for individuals with diabetes but also for health-conscious individuals seeking to understand and improve their metabolic health. Abbott’s Lingo, notably, is indicated for over-the-counter (OTC) use (FDA-approved in 2024 according to CNET), expanding access to CGM without requiring medical intervention. The endorsement of Lingo by digital health companies like Withings reflects the broader industry trend of integrating wearable technology and biosensors into mainstream preventive care and health management. Non-invasiveness and ease of use are paramount factors for wider adoption in this sector.

Strategic Significance and Outlook

The proliferation of non-invasive CGM devices like the Lingo biosensor has the potential to profoundly transform health management. In the future, these multi-functional sensors are expected to evolve to non-invasively and simultaneously measure other crucial biomarkers beyond glucose, such as ketone bodies, lactate, and electrolytes. Furthermore, integration with AI is anticipated to provide advanced personalized health predictions and interventions based on individual biometric data, lifestyle, and even genetic information. This evolution will establish powerful tools for individuals to more actively manage their health across a wide range of applications, including diabetes prevention, weight management, and athletic performance enhancement.

Source: https://www.withings.com/en-in/products/lingo

Get our weekly technology intelligence — free

Receive an infographic that lets you judge at a glance whether each field’s analysis report is worth reading.

Subscribe Free — Weekly Tech Intelligence

By subscribing, you’ll receive Troy-Technical’s weekly technology intelligence newsletter.